The SUMOylated RREB1 interacts with KDM1A to induce 5-fluorouracil resistance via upregulating thymidylate synthase and activating DNA damage response pathway in colorectal cancer

Abstract

Chemoresistance is one main cause of failure in colorectal cancer (CRC) treatment. The role of transcription factor Ras-responsive element binding protein 1 (RREB1) remains unclarified in CRC chemoresistance. Herein, we reveal that RREB1 functions as an oncogene to promote cell proliferation and 5-fluorouracil (5-FU) chemoresistance in CRC, and SUMOylation is required for RREB1 to exert its oncogenic role in CRC. RREB1 induced cell cycle arrest at the S-phase and a decreased apoptosis rate under 5-FU exposure. Mechanistically, the interaction of RREB1 with lysine demethylase 1A (KDM1A) elevated expression of 5-FU targeting proteins thymidylate synthase (TS) and thymidine kinase (TK1) to maintain the nucleotide pool balance under 5-FU treatment, and enhanced activation of Chk1-mediated DNA damage response (DDR) pathway. The deSUMOylation of RREB1 resulted in a reduced interaction of RREB1 with KDM1A, contributing to a downregulation of TS expression and a less activation of DDR pathway. Moreover, KDM1A knockdown improved the DNA damage and reduced RREB1-mediated resistance to 5-FU. These findings provide new insights into RREB1-mediated chemotherapy responses in CRC and indicate RREB1 is a potential target for overcoming 5-FU resistance.

Keywords

5-fluorouracil / chemoresistance / colorectal cancer / DNA damage response / KDM1A / RREB1 / SUMOylation

References

[1] Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020; 70(3): 145-164.

[2] Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003; 3(5): 330-338.

[3] McQuade RM, Stojanovska V, Bornstein JC, Nurgali K. Colorectal cancer chemotherapy: the evolution of treatment and new approaches. Curr Med Chem. 2017; 24(15): 1537-1557.

[4] Shah MA, Schwartz GK. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res. 2001; 7(8): 2168-2181.

[5] Sethy C, Kundu CN. 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: implication of DNA repair inhibition. Biomed Pharmacother. 2021; 137: 111285.

[6] Sharma A, Singh K, Almasan A, Histone H2AX phosphorylation: a marker for DNA damage. Methods Mol Biol. 2012; 920: 613-626.

[7] Tomasini PP, Guecheva TN, Leguisamo NM, et al. Analyzing the opportunities to target DNA double-strand breaks repair and replicative stress responses to improve therapeutic index of colorectal cancer. Cancers (Basel). 2021; 13(13): 3130.

[8] Reilly NM, Novara L, Di Nicolantonio F, Bardelli A, Exploiting DNA repair defects in colorectal cancer. Mol Oncol. 2019; 13(4): 681-700.

[9] Deng YN, Xia ZJ, Zhang P, Ejaz S, Liang SF. Transcription factor RREB1: from target genes towards biological functions. Int J Biol Sci. 2020; 16(8): 1463-1473.

[10] Su J, Morgani SM, David CJ, et al. TGF-beta orchestrates fibrogenic and developmental EMTs via the RAS effector RREB1. Nature. 2020; 577(7791): 566.

[11] Morgani SM, Su J, Nichols J, Massague J, Hadjantonakis AK. The transcription factor Rreb1 regulates epithelial architecture, invasiveness, and vasculogenesis in early mouse embryos. Elife. 2021; 10: e64811.

[12] Liu H, Hew HC, Lu ZG, Yamaguchi T, Miki Y, Yoshida K. DNA damage signalling recruits RREB-1 to the p53 tumour suppressor promoter. Biochem J. 2009; 422(3): 543-551.

[13] Chen B, Deng YN, Wang X, et al. miR-26a enhances colorectal cancer cell growth by targeting RREB1 deacetylation to activate AKT-mediated glycolysis. Cancer Lett. 2021; 521: 1-13.

[14] Nayak A, Muller S. SUMO-specific proteases/isopeptidases: SENPs and beyond. Genome Biol. 2014; 15(7): 422.

[15] Bailey D, O’Hare P. Characterization of the localization and proteolytic activity of the SUMO-specific protease, SENP1. J Biol Chem. 2004; 279(1): 692-703.

[16] Hendriks IA, D’Souza RCJ, Yang B, Vries MV, Mann M, Vertegaal ACO. Uncovering global SUMOylation signaling networks in a site-specific manner. Nat Struct Mol Biol. 2014; 21(10): 927-936.

[17] Noordhuis P, Holwerda U, Van der Wilt CL, et al. 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers. Ann Oncol. 2004; 15(7): 1025-1032.

[18] Mah LJ, El-Osta A, Karagiannis TC. Gamma H2AX: a sensitive molecular marker of DNA damage and repair. Leukemia. 2010; 24(4): 679-686.

[19] Smits VAJ, Reaper PM, Jackson SP. Rapid PIKK-dependent release of Chk1 from chromatin promotes the DNA-damage checkpoint response. Curr Biol. 2006; 16(2): 150-159.

[20] Vasaikar S, Huang C, Wang X, et al. Proteogenomic analysis of human colon cancer reveals new therapeutic opportunities. Cell. 2019; 177(4): 1035-1049. e19.

[21] Li L, Wen J, Tuo QH, Liao DF. Effects of SUMOylation on the subcellular localization and function of DAXX. Sheng Li Xue Bao. 2013; 65(1): 89-95.

[22] Xu Y, Wu W, Han Q, et al. Post-translational modification control of RNA-binding protein hnRNPK function. Open Biol. 2019; 9(3): 180239.

[23] Peters GJ, Backus HHJ, Freemantle S, et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. BBA-Mol Basis Dis. 2002; 1587(2-3): 194-205.

[24] McAllister KA, Yasseen AA, McKerr G, Downes CS, McKelvey-Martin VJ. FISH comets show that the salvage enzyme TK1 contributes to gene-specific DNA repair. Front Genet. 2014; 5:eCollection 00233.

[25] Antona A, Leo G, Favero F, et al. Targeting lysine-specific demethylase 1 (KDM1A/LSD1) impairs colorectal cancer tumorigenesis by affecting cancer cells stemness, motility, and differentiation. Cell Death Discov. 2023; 9(1): 201.

[26] Ray SK, Li HJ, Metzger E, Schüle R, Leiter AB. CtBP and associated LSD1 are required for transcriptional activation by NeuroD1 in gastrointestinal endocrine cells. Mol Cell Biol. 2014; 34(12): 2308-2317.

[27] Kent OA, Saha M, Coyaud E, et al. Haploinsufficiency of RREB1 causes a Noonan-like RASopathy via epigenetic reprogramming of RAS-MAPK pathway genes. Nat Commun. 2020; 11(1): 4673.

[28] Sheng ZH, Cao X, Deng YN, Zhao X, Liang S. SUMOylation of AnxA6 facilitates EGFR-PKCα complex formation to suppress epithelial cancer growth. Cell Commun Signal. 2023; 21: 189.

[29] Liang ZW, Yang YF, He Y, et al. SUMOylation of IQGAP1 promotes the development of colorectal cancer. Cancer Lett. 2017; 411: 90-99.

[30] He Y, Wang XX, Lu WL, et al. PGK1 contributes to tumorigenesis and sorafenib resistance of renal clear cell carcinoma via activating CXCR4/ERK signaling pathway and accelerating glycolysis. Cell Death Dis. 2022; 13(2): 118.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.